FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma By Ogkologos - October 27, 2025 227 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the C-POST study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in... May 3, 2022 Study Identifies Hundreds of Potential Targets for Cancer Drugs September 11, 2024 Nivolumab Injections Could Make Treatment Easier for More People with Cancer March 13, 2024 What People With Breast Cancer and Survivors Should Know About Exercising... October 4, 2022 Load more HOT NEWS Brain Cancer Cells Hijack Gene “On Switches” to Drive Tumor Growth Does Sugar Cause Cancer? Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? How Adolescent and Young Adult Cancer Survivors Can Cope With the...
